Plain-English translation of NCT05476796 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of three medications—, , and (an immunotherapy drug)—to see if they work better than the standard chemotherapy combination called FOLFOX for treating advanced stomach and esophageal cancers. Researchers want to know if the newer medication combination helps people live longer and has fewer side effects, especially for patients who may be frailer or less able to tolerate intense treatments. About 118 people will be randomly assigned to receive either the new combination or the standard treatment.
Current chemotherapy for advanced stomach and esophageal cancer can be very tough on the body, and doctors are looking for gentler options that still work well. This medication may be easier for patients to tolerate while still fighting the cancer effectively.
You will be randomly assigned to one of two treatment groups. You'll receive intravenous chemotherapy infusions every 2 weeks, and if assigned to include the immunotherapy drug, those infusions will also happen every 2 weeks. Some patients will also take an oral medication twice daily for 5 days, then rest for 9 days, and repeat this cycle. Treatment continues until your cancer stops responding, intolerable side effects occur, or you've been treated for up to 2 years. You'll have regular blood tests and scans to monitor how well the treatment is working and check for side effects.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
France